Acumen jumps after equity raise to advance Alzheimer's drug development

JCR Pharmaceuticals

16/03/2026 12:02

** Acumen Pharmaceuticals ABOS.O shares jump 13.2% premarket to $3.71, highest since May 2024, after it raises equity to fund experimental Alzheimer's disease drug

** Newtown, Massachusetts-based ABOS says sold $35.75 mln of shares (approx 10.8 mln) at $3.30 in private placement led by existing investor RA Capital Management

** ABOS stock closed down 0.9% at $3.27 on Fri, trimming YTD gain to 55%

** Co expects to use proceeds to primarily support its Enhanced Brain Delivery (EBD) program, including ongoing preclinical development of a lead candidate molecule, and for other purposes

** ABOS currently focused on advancing its lead product candidate, sabirnetug (ACU193), a humanized monoclonal antibody in ongoing Phase 2 clinical trial in early symptomatic Alzheimer’s disease patients

** Co also announces preclinical drug data, including in vitro, in vivo and non-human primate (NHP) study results, that support development candidates in its transferrin-receptor as part of collaboration with Japan's JCR Pharmaceuticals 4552.T

** EBD candidates achieved 14-40x higher brain levels in NHPs compared to native antibodies at 24 hours, and indicate low potential for anemia with no adverse effects observed, according to the presentation

** ABOS has ~60.6 mln shares outstanding for nearly $200 mln market cap

** Avg rating of 6 analysts is "strong buy"; median PT $7, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))